Traditional Chinese medicine composition for treating stationary-phase COPD (chronic obstructive pulmonary disease)

Abstract

The invention provides traditional Chinese medicine composition for treating the stationary-phase COPD (chronic obstructive pulmonary disease). The composition comprises raw materials in parts by weight as follows: 47 parts of codonopsis radix, 59 parts of light wheat, 35 parts of fried largehead atractylodes rhizome, 23 parts of prepared pinellia tuber, 47 parts of dried tangerine peel, 35 parts of perilla fruit, 35 parts of divaricate saposhnikovia root, 35 parts of poria cocos, 59 parts of raw coix seed, 35 parts of honey-fried common coltsfoot flower, 35 parts of baical skullcap root, 35 parts of bulbus fritillariae pallidiflorae and 35 parts of honey-fried loquat leaf. The traditional Chinese medicine composition can prolong the second-time acute exacerbation time interval of a COPD patient by 77.68 days, decrease acute exacerbation times by 1.46 times per half a year, shorten the acute exacerbation duration by 2.93 days, decrease mMRC and CAT scores, improve clinical symptoms such as coughing, expectoration, shortness of breath, spontaneous perspiration, lacking in strength and the like, and enhance the exercise tolerance (that is, the 6MWD is increased). The composition has no side effect in a taking process of the clinical patient, so that the composition is a safe and effective prescription for treating the stationary-phase COPD.

Description

technical field [0001] The invention relates to a traditional Chinese medicine composition for treating stable chronic obstructive pulmonary disease. Background technique [0002] Chronic obstructive pulmonary disease (COPD) is a disease characterized by airflow limitation. In my country, COPD patients aged 15 and above account for 3%, and it is the first cause of death in rural areas, and it is the first in the World Health Organization's evaluation of my country's disease burden sequence bit. Research by the World Bank and WHO shows that COPD was the twelfth leading cause of death and disability in the world in 1990, but it will become the third leading cause of death and disability in the world by 2020. Although all countries in the world have invested a large amount of manpower and material resources in the research of COPD, and formulated corresponding diagnosis and treatment standards, the prevalence, mortality, disability rate and the resulting burden of disease on th...

AI Technical Summary

Problems solved by technology

[0003] At present, there is no definite curative effect of the drugs for the treatment of COPD in the stable stage, and there are no therapeutic drugs that have undergone formal clinical trials on the market. The traditional Chinese medicines currently used in the clinical treatment of COPD in the stable stage are mostly decoctions and non-decoction powders , the preparation process of the decoction is complicated, and the taste is bitter and astringent when taken, the taste is poor, and it has certain irritation to the gastrointestinal tract

Images